Psyence Biomedical Ltd(PBM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 21 at 7:42 PM ET (Korea 10/22 08:42)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 72.19% | Shs Outstand | 3.8M | Perf Week | 9.44% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.1M | Perf Month | -25.9% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 13.24% | Short Float | 2.53% | Perf Quarter | 60.28% |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 7.25% | Short Ratio | 0.33 | Perf Half Y | -49.61% |
| Sales | - | P/B | 0.11 | EPS next 5Y | - | ROA | - | Short Interest | 0.03M | Perf YTD | -4.01% |
| Book/sh | 39.62 | P/C | 2.39 | EPS past 3/5Y | - | ROE | - | 52W High | -79.22% ($21.75) | Perf Year | -79.01% |
| Cash/sh | 1.89 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 135.42% ($1.92) | Perf 3Y | -99.99% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -105.54% | Gross Margin | - | Volatility(W/M) | 8.31% 9.02% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.42 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.09 | EPS Q/Q | -23614.18% | Profit Margin | - | RSI (14) | 44.16 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.09 | Sales Q/Q | - | SMA20 | -8.25% ($4.93) | Beta | 1.69 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -6.78% ($4.85) | Rel Volume | 0.48 | Prev Close | $4.24 |
| Employees | 12 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 12.08% ($4.03) | Avg Volume(3M) | 0.08M | Price | $4.52 |
| IPO | 2021/12/10 | Option/Short | No/Yes | Trades | 297 | Volume | 39,322 | Change | 6.6% |
🧠 Development of natural psychoactive medications. Psilocybin and ibogaine therapeutics. Phase IIb psychotherapy for cancer patients; clinical trials begin in Australia.
Over the past 1 year, on the lower side
79% below its 1-year high.
Traded less than usual. That is 48% of its average volume.
Holding long would have lost money
Bought 3 years ago, your return today would be -100.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 13.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
PSIL AdvisorShares Psychedelics ETF <0.01% It ranks #471 of 595 in the industry
Based on market cap of $17M.
COCP#470 Cocrystal Pharma Inc $18M PER - PBM#471 Psyence Biomedical Ltd $17M PER - 
ATYR#472 Atyr Pharma Inc $17M PER - 
JSPR#473 Jasper Therapeutics Inc $17M PER - 
KTTA#474 Pasithea Therapeutics Corp $16M PER - 
FAQ
What kind of company is PBM?
PBM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PBM?
The market cap of PBM is approximately $17M, ranking 5,266 within its sector.
What is the 52-week high and low for PBM?
PBM has recorded a 52-week high of $21.75 and a low of $1.92.
